aducanumab

With Medicare Undecided On Whether To Pay, Alzheimer’s Drug Maker Biogen Offers Free Doses

A funny thing happened on the way to that $56,00-a-year Alzheimer’s drug: Payers are reluctant to pay, providers are reluctant to prescribe, and the price is coming down—at least for some patients. It is a tale that could push Congress to allow Medicare to negotiate drug prices. Reuters reports that Biogen, which sells the controversial medication it calls Aduhelm, is [...]

By Howard Gleckman|2021-09-01T15:11:40-04:00September 1st, 2021|dementia|0 Comments

What Does FDA’s Approval Of A New Alzheimer’s Drug Mean?

In a highly controversial decision, the FDA gave accelerated approval to the first drug that could slow the progression of Alzheimer’s disease. But the approval does not say the FDA thinks the drug actually will treat the disease. Rather, FDA carefully states that the drug, with the chemical name aducanumab and the brand name Aduhelm, reduces a substance on the [...]

By Howard Gleckman|2021-06-07T17:50:37-04:00June 7th, 2021|dementia|5 Comments